SRZN vs ATYR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ATYR Captures Institutional Edge (2โ1 Pillars ยท 2โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to aTyr Pharma, Inc. Common Stock (ATYR) driven by superior Momentum & Technical, Options & Structure while SRZN counters with relative strength in Growth & Margin. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus ATYR at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against ATYR sits in UNCLASSIFIED (36th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SRZN Revenue | ATYR Revenue | SRZN Op. Margin | ATYR Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | N/A | $0M | N/A | -5445.0% | ATYR |
| FY2020 | N/A | $10M | N/A | -152.2% | ATYR |
| FY2022 | $10M | $10M | -354.7% | -446.8% | SRZN |
| FY2023 | N/A | $0M | N/A | -15557.8% | ATYR |
| FY2024 | $10M | $0M | -239.7% | -28899.6% | SRZN |
| FY2025 | $0M | $0M | -1210.6% | -40856.3% | SRZN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SRZN | ATYR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $602.5M | $15.6M | Larger Scale | SRZN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +408.6% | +0.0% | Higher Growth | SRZN |
| Operating Margin (TTM) Profitability | -485.4% | 0.0% | Higher Margin | ATYR |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -62.8% | -93.7% | Higher ROE | SRZN |
| 52-Week Range Position Momentum | 69% ($12โ$38) | 60% ($0โ$8) | Stronger Trend | SRZN |
| Beta / 30D Volatility Risk Regime | 1.28ฮฒ ยท 66% Vol | -9.57ฮฒ ยท 13806% Vol | Lower Realized Risk | SRZN |
| Unified Institutional Score Composite Signal | 33.2 / 100 (SELL) | 34.3 / 100 (SELL) | Higher Composite | ATYR |